Lumigan: Advanced Glaucoma Treatment for Intraocular Pressure Control
| Product dosage: 0.03mg | |||
|---|---|---|---|
| Package (num) | Per bottle | Price | Buy |
| 1 | $53.45 | $53.45 (0%) | 🛒 Add to cart |
| 2 | $50.93 | $106.91 $101.87 (5%) | 🛒 Add to cart |
| 3 | $50.43 | $160.36 $151.29 (6%) | 🛒 Add to cart |
| 4 | $50.18 | $213.82 $200.71 (6%) | 🛒 Add to cart |
| 5 | $49.82 | $267.27 $249.12 (7%) | 🛒 Add to cart |
| 6 | $49.76 | $320.73 $298.54 (7%) | 🛒 Add to cart |
| 7 | $49.56 | $374.18 $346.95 (7%) | 🛒 Add to cart |
| 8 | $49.55 | $427.63 $396.37 (7%) | 🛒 Add to cart |
| 9 | $49.53 | $481.09 $445.79 (7%) | 🛒 Add to cart |
| 10 | $49.42
Best per bottle | $534.54 $494.20 (8%) | 🛒 Add to cart |
Synonyms | |||
Lumigan (bimatoprost ophthalmic solution) 0.01% is a prescription medication specifically formulated to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. As a prostaglandin analog, it represents a first-line therapeutic option endorsed by ophthalmological guidelines worldwide. Its mechanism of action enhances uveoscleral outflow, offering a physiological approach to IOP management. Clinicians favor Lumigan for its efficacy, tolerability, and once-daily dosing regimen which supports patient adherence.
Features
- Active ingredient: Bimatoprost 0.01%
- Pharmaceutical form: Sterile ophthalmic solution
- Presentation: 2.5 mL or 5 mL translucent plastic bottle with tamper-evident closure
- Preservative: Benzalkonium chloride 0.02%
- pH: Approximately 7.0–7.4
- Osmolality: Approximately 290 mOsm/kg
Benefits
- Significantly reduces intraocular pressure, slowing glaucoma progression
- Once-daily administration supports consistent patient compliance
- Demonstrates superior IOP-lowering efficacy compared to many beta-blockers
- Minimal systemic side effects due to localized action
- May enhance eyelash growth as a secondary cosmetic effect
- Compatible with other topical ocular medications when properly timed
Common use
Lumigan is primarily indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. It is often prescribed as monotherapy but may be used concomitantly with other IOP-lowering agents when additional pressure control is required. The medication is suitable for long-term management of chronic conditions and is typically prescribed following comprehensive ophthalmological evaluation.
Dosage and direction
The recommended dosage is one drop in the affected eye(s) once daily in the evening. Administration should occur at approximately the same time each day. Patients should remove contact lenses prior to application and wait at least 15 minutes before reinsertion. Proper instillation technique involves tilting the head backward, pulling down the lower eyelid, applying one drop to the conjunctival sac, and closing the eye for 1–2 minutes while applying gentle pressure to the nasolacrimal duct to minimize systemic absorption.
Precautions
Patients should be advised that Lumigan may gradually increase brown pigmentation of the iris, which may be permanent. Eyelid skin darkening may occur and might be reversible upon discontinuation. There is potential for gradual changes to eyelashes and vellus hair in the periorbital region. Use with caution in patients with intraocular inflammation, aphakic patients, pseudophakic patients with torn posterior lens capsule, or patients at risk for macular edema. Patients should be monitored for bacterial keratitis associated with multiple-dose containers.
Contraindications
Lumigan is contraindicated in patients with hypersensitivity to bimatoprost or any component of the formulation. It should not be used in cases of active intraocular inflammation unless the potential benefits outweigh the risks. Use during pregnancy only if clearly needed, as reproductive studies have shown adverse effects in animals. Not recommended for use while breastfeeding due to potential secretion in human milk.
Possible side effects
The most common ocular adverse reactions (approximately 15-45%) include conjunctival hyperemia, growth of eyelashes, and ocular pruritus. Approximately 3-10% of patients experience dry eye, visual disturbance, ocular burning, foreign body sensation, eye pain, pigmentation of the periocular skin, blepharitis, cataract, superficial punctate keratitis, eyelid erythema, ocular irritation, and eyelash darkening. Between 1-3% may experience eye discharge, tearing, photophobia, allergic conjunctivitis, asthenopia, increased iris pigmentation, and conjunctival edema. Serious but rare side effects include macular edema, iritis, uveitis, and periorbital tissue atrophy.
Drug interaction
Although systemic absorption is low, potential interactions may occur with other prostaglandin analogs. Concurrent use with other eye medications should be separated by at least 5 minutes to prevent wash-out effects. No clinically significant interactions have been observed with systemic medications, though theoretical potential exists for interaction with drugs affecting prostaglandin pathways. Patients using multiple topical ophthalmic medications should be monitored for additive effects on ocular surface health.
Missed dose
If a dose is missed, patients should apply the drop as soon as possible. However, if it is nearly time for the next scheduled dose, the missed dose should be skipped and the regular dosing schedule resumed. Patients should never apply double doses to compensate for a missed administration. Consistent evening administration helps maintain stable intraocular pressure control throughout the 24-hour cycle.
Overdose
Ocular overdose may be flushed from the eye(s) with warm tap water. Systemic overdose is unlikely due to low absorption, but symptoms might include headache, dizziness, or nausea. In case of accidental ingestion, medical attention should be sought. Supportive care should be provided based on symptoms. There is no specific antidote for bimatoprost overdose.
Storage
Store at 2°C to 25°C (36°F to 77°F). Protect from light. Keep the bottle tightly closed when not in use. Discard any unused solution 4 weeks after opening the bottle. Do not freeze. Keep out of reach of children and pets. Do not use if the solution changes color or becomes cloudy.
Disclaimer
This information does not replace professional medical advice. Patients should consult their ophthalmologist for proper diagnosis and treatment recommendations. Individual results may vary based on specific medical conditions and adherence to prescribed therapy. Always follow the exact instructions provided by your healthcare provider.
Reviews
Clinical studies demonstrate Lumigan’s consistent efficacy in reducing intraocular pressure by 25-33% from baseline. The FDA approval was based on multiple randomized controlled trials involving over 1,700 patients. Ophthalmologists report high satisfaction with Lumigan’s performance in clinical practice, particularly noting its reliable IOP control and favorable safety profile. Patient surveys indicate good tolerability and satisfaction with once-daily dosing convenience, though some report concerns about cosmetic side effects. Long-term studies confirm maintained efficacy over 24 months of continuous use.